On August 10, MAO GEPING rose 5.08% in regular trading, trading at HK$56.85/share, with turnover of HK$128 million.

On the news front, the beauty sector rallied broadly, with sector peers CHICMAX up 6.42% and GIANT BIOGENE up 4.36%, reflecting strong industry linkage. Bank of America Securities recently reiterated its Buy rating on MAO GEPING with a target price of HK$95, projecting first-half revenue growth exceeding 20% and net profit growth surpassing 30%, driven by an increasing share of higher-margin online channels. Management expects revenue growth to accelerate in the second half to achieve the full-year 30% target.

As the interim results window approaches, market optimism around earnings delivery is drawing capital inflows. The company reported full-year revenue of RMB 50.5 billion for the prior fiscal year with net profit growth of 36.8%, and multiple brokerages including Guotai Haitong and CICC have highlighted its strong brand momentum and unique positioning in Eastern aesthetics-inspired premium cosmetics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)